Search This Blog

Wednesday, September 21, 2022

Argenx Submits FDA Application for Myasthenia Gravis Med

Submission based on positive data from the Phase 3 ADAPT-SC trial demonstrating noninferiority of subcutaneous (SC) efgartigimod compared to intravenously administered VYVGART® (efgartigimod alfa-fcab) based on total immunoglobulin G (IgG) reduction at day 29

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.